Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

Translated title of the contribution: Transarterial chemoembolization for treatment of hepatocellular carcinoma

Mickael Lesurtel, Zakiyah Kadry, Thomas Pfammatter, Pierre Alain Clavien

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

Original languageFrench
Pages (from-to)1074-1081
Number of pages8
JournalMedecine et Hygiene
Volume61
Issue number2438
StatePublished - May 21 2003

Fingerprint

Hepatocellular Carcinoma
Survival
Evidence-Based Medicine
Liver
Blood Vessels
Therapeutics
Randomized Controlled Trials
Morbidity
Drug Therapy
Mortality
Research

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lesurtel, Mickael ; Kadry, Zakiyah ; Pfammatter, Thomas ; Clavien, Pierre Alain. / Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable. In: Medecine et Hygiene. 2003 ; Vol. 61, No. 2438. pp. 1074-1081.
@article{f9e6575c3a3b411a94115a755e416c7c,
title = "Place de la chimio-embolisation dans le traitement du carcinome h{\'e}patocellulaire non r{\'e}s{\'e}cable",
abstract = "Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15{\%} and 6{\%}, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.",
author = "Mickael Lesurtel and Zakiyah Kadry and Thomas Pfammatter and Clavien, {Pierre Alain}",
year = "2003",
month = "5",
day = "21",
language = "French",
volume = "61",
pages = "1074--1081",
journal = "Revue Medicale Suisse",
issn = "1660-9379",
publisher = "Editions Medecine et Hygiene",
number = "2438",

}

Lesurtel, M, Kadry, Z, Pfammatter, T & Clavien, PA 2003, 'Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable', Medecine et Hygiene, vol. 61, no. 2438, pp. 1074-1081.

Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable. / Lesurtel, Mickael; Kadry, Zakiyah; Pfammatter, Thomas; Clavien, Pierre Alain.

In: Medecine et Hygiene, Vol. 61, No. 2438, 21.05.2003, p. 1074-1081.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

AU - Lesurtel, Mickael

AU - Kadry, Zakiyah

AU - Pfammatter, Thomas

AU - Clavien, Pierre Alain

PY - 2003/5/21

Y1 - 2003/5/21

N2 - Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

AB - Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=0038148399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038148399&partnerID=8YFLogxK

M3 - Review article

VL - 61

SP - 1074

EP - 1081

JO - Revue Medicale Suisse

JF - Revue Medicale Suisse

SN - 1660-9379

IS - 2438

ER -